Literature DB >> 16955467

Detection in primary chronic myeloid leukaemia cells of p210BCR-ABL1 in complexes with adaptor proteins CBL, CRKL, and GRB2.

Hetal Patel1, Stephen B Marley, Myrtle Y Gordon.   

Abstract

Chronic myeloid leukemia (CML) arises as a consequence of the expression of a chimeric fusion protein, p210BCR-ABL1, which is localized to the cytoplasm and has constitutive protein tyrosine kinase activity. Extensive publications report that p210BCR-ABL1 complexed with multiple cytoplasmic proteins can modulate several cell signaling pathways. However, while altered signaling states can be demonstrated in primary CML material, most of the reported analytical work on complexed proteins has been done in cell lines expressing p210BCR-ABL1. This has been necessary because primary hemopoietic cell lysates contain a degradative activity which rapidly and permanently destroys p210BCR-ABL1, precluding accurate p210BCR-ABL1 quantification by Western blotting or investigation of coimmunoprecipitating proteins in primary cells. This degradative activity has proven intractable to inhibition by conventional protease inhibitors. We show here that the degradative activity in primary cells is associated with cell lysosomes and is most likely to be an acid-dependent hydrolase. By lysing primary hemopoietic cells at high pH, we have demonstrated substantial inhibition of the p210BCR-ABL1-degradative activity and now report, to the best of our knowledge, the first published demonstration by coimmunoprecipitation of the association between p210BCR-ABL1 and cytoplasmic effector proteins in primary CML material. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16955467     DOI: 10.1002/gcc.20377

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

1.  Enzymatic-based cytometry, a sensitive single-cell cytometric method to assess BCR-ABL1 activity in CML.

Authors:  Jinzhu Yu; Ki Oh; Sitapriya Moorthi; Ling Li; Helmut H Strey; Michael Schuster; Chiara Luberto; Phenix-Lan Quan; Eric Brouzes
Journal:  Lab Chip       Date:  2020-03-03       Impact factor: 6.799

2.  Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity.

Authors:  Christian Boni; Massimiliano Bonifacio; Marzia Vezzalini; Luigi Scaffidi; Luisa Tomasello; Laurie L Parker; Diego Boscarino; Dino Paladin; Mauro Krampera; Claudio Sorio
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

3.  Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Authors:  Ji Wu; Feng Meng; Ling-Yuan Kong; Zhenghong Peng; Yunming Ying; William G Bornmann; Bryant G Darnay; Betty Lamothe; Hanshi Sun; Moshe Talpaz; Nicholas J Donato
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

4.  The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib.

Authors:  Jamshid Sorouri Khorashad; Simon Wagner; Liat Greener; David Marin; Alistair Reid; Dragana Milojkovic; Hetal Patel; Shaun Willimott; Katy Rezvani; Gareth Gerrard; Sandra Loaiza; John Davis; John Goldman; Junia Melo; Jane Apperley; Letizia Foroni
Journal:  Haematologica       Date:  2009-04-18       Impact factor: 9.941

Review 5.  Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.

Authors:  Christine Victoria Ichim
Journal:  Stem Cells Transl Med       Date:  2014-03-05       Impact factor: 6.940

6.  Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells.

Authors:  Oshrat Hershkovitz Rokah; Galit Granot; Adelina Ovcharenko; Shira Modai; Metsada Pasmanik-Chor; Amos Toren; Noam Shomron; Ofer Shpilberg
Journal:  PLoS One       Date:  2012-04-12       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.